AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03652441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
Study NCT02532127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva sampling
Description: Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
Study NCT01399918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus and bevacizumab
Description: Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
Study NCT01731223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group treatment for insomnia
Description: Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
Study NCT05624671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bupivacaine,fentanyl
Description: According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
Study NCT00737698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
Study NCT00737698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation
Description: Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
Study NCT00753064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiscorpion venom serum(AScVS).
Description: AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 > 10-15 3 6 >15- 21 4 8
Study NCT00753064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T.Prazosin
Description: Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
Study NCT00753064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AScVS + Prazosin
Description: Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
Study NCT01755572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
Study NCT01755572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
Study NCT01755572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
Study NCT01755572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
Study NCT00672737 — intervention group
Intervention type: DRUG
Intervention: Remifentanil
Description: Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
Study NCT00672737 — intervention group
Intervention type: PROCEDURE
Intervention: Cold pain threshold and tolerance
Description: Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
Study NCT00672737 — intervention group
Intervention type: DEVICE
Intervention: Heat pain threshold and tolerance
Description: TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
Study NCT00672737 — intervention group
Intervention type: PROCEDURE
Intervention: Polysomnography
Description: All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
Study NCT04652505 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT00201877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 \& 14.~Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23.
Study NCT00201877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.~Maintenance: 375 mg/m2 day 1 weekly x 4 weeks.
Study NCT03420248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere
Description: One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.
Study NCT01361542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti TNF alpha agent
Description: Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
Study NCT01361542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti TNF alpha therapy
Description: Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
Study NCT02573389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific or Cook pancreatic duct stents
Description: Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
Study NCT01260818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
Study NCT01260818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
Study NCT01734733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NTCELL
Study NCT02387268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleanC system
Description: Cleansing liquid and fecal matter during a standard colonoscopy procedure
Study NCT00671177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water immersion colonoscopy
Description: instillation of 300cc of water in the rectum
Study NCT00671177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard air colonoscopy
Description: air instillation in colon for visualization
Study NCT00781105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg/day, oral tablets, once daily, 52 weeks
Study NCT03780361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Total 5 times of monthly intravitreal aflibercept injections will be done.
Study NCT00409721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study NCT02429453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four Factor Prothrombin Complex Concentrate
Description: A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
Study NCT02429453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: A pooled collection of plasma from donors
Study NCT03506074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flavor test
Description: The flavor test was developed, validated and patented (patent no. 0001426253 of the Italian Ministry for the Economic Development). It consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for Italian people. At each administration, participants were invited to identify the aromatic by making a choice from 5 proposed items. A total of 21 aromatics (including one blank) were administered sequentially. The flavor score (FS) was calculated as the sum of correctly identified aromatics and ranged from 0 to 21.
Study NCT02893839 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prick to prick test
Study NCT01800890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast A
Description: Coloplast A is a newly developed 2-piece ostomy appliance
Study NCT01800890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast A
Description: Coloplast A is a newly developed 2-piece ostomy appliance
Study NCT01800890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast B
Description: Coloplast B is a newly developed 2-piece ostomy appliance
Study NCT01800890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast B
Description: Coloplast B is a newly developed 2-piece ostomy appliance
Study NCT01800890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast C
Description: Coloplast C is a newly developed 2-piece ostomy appliance
Study NCT01800890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SenSura Click
Description: The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
Study NCT03221998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV paracetamol
Description: 100 gram paracetamol infusion for moderate pain management
Study NCT03221998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV saline (NaCl 0.9 %)
Description: 100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
Study NCT01800890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Click
Description: The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
Study NCT00630734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 1-4
Study NCT02589080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-invasive sensory feedback
Description: A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback.
Study NCT00988000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telephone consultation
Description: alternative to face to face consultation for new referrals
Study NCT00988000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: no alternative to face to face consultation
Study NCT04263246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoDyNAmic
Description: PhytoDyNAmic (6 capsules per day)
Study NCT04263246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: Inulin (6 capsules per day)
Study NCT03131115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Crural Strut Graft
Description: surgical technique as described
Study NCT03131115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Anchored Suspension
Description: Surgical technique as described
Study NCT00630734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600mg by mouth twice daily on days 12-18
Study NCT00630734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg by mouth twice daily on days 12-18
Study NCT00630734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 15-18
Study NCT00630734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout
Description: Washout (no medication) on days 5-11.
Study NCT04536129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (CORTIVIS ®)
Description: Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
Study NCT04536129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone (CORTIVIS ®)
Description: Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
Study NCT01735227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
Study NCT01735227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
Study NCT04168983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sophrology
Description: Sophrology session provided by a nurse sophrologist in addition to the usual care during BMAB
Study NCT05216822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
Study NCT05216822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
Study NCT02489968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg + linagliptin 5 mg
Description: empagliflozin low dose + linagliptin once daily
Study NCT02489968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Description: empagliflozin low dose once daily
Study NCT02489968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg + linagliptin 5 mg
Description: empagliflozin high dose + linagliptin once daily
Study NCT02489968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Description: empagliflozin high dose once daily
Study NCT02489968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00507403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Study NCT00507403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Study NCT01214642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Administered subcutaneously
Study NCT01214642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously
Study NCT00724165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Culturally-modified, individually tailored physical activity print materials
Study NCT00724165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Bilingual health education booklets
Study NCT04822077 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: * Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)
Study NCT03993262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
Study NCT03993262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
Study NCT03028675 — intervention group
Intervention type: OTHER
Intervention: MRI Scan
Description: MRI scans will consist of a 1-hour brain scan for both patients and controls.
Study NCT00766597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
Study NCT03166020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: An occupational therapist will be required only for patient installation in front of the table.
Study NCT03166020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: An occupational therapist will be required only for patient installation in front of the table.
Study NCT02565602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ca-41(isotope tracer)
Description: Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
Study NCT02565602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sr-84 (isotope tracer)
Description: Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
Study NCT02565602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: One tablet daily (400IU per tablet)